Go Pro
→ Porter flew 3,300 miles to investigate this system (From Porter & Company) (Ad)tc pixel Free HCM Stock Alerts

HUTCHMED (HCM) Competitors

HUTCHMED logo
GBX 170 0.00 (0.00%)
As of 07/31/2026 12:01 PM Eastern
Compare

HCM vs. DPH, HIK, INDV, VEC, and ERGO

Should you buy HUTCHMED stock or one of its competitors? MarketBeat compares HUTCHMED with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with HUTCHMED include Dechra Pharmaceuticals (DPH), Hikma Pharmaceuticals (HIK), Indivior (INDV), Vectura Group (VEC), and Ergomed (ERGO). These companies are all part of the "pharmaceuticals" industry.

How does HUTCHMED compare to Dechra Pharmaceuticals?

Dechra Pharmaceuticals (LON:DPH) and HUTCHMED (LON:HCM) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

105.5% of Dechra Pharmaceuticals shares are held by institutional investors. Comparatively, 20.4% of HUTCHMED shares are held by institutional investors. 9.3% of Dechra Pharmaceuticals shares are held by company insiders. Comparatively, 2.8% of HUTCHMED shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Dechra Pharmaceuticals' average media sentiment score of 0.00 equaled HUTCHMED'saverage media sentiment score.

Company Overall Sentiment
Dechra Pharmaceuticals Neutral
HUTCHMED Neutral

Dechra Pharmaceuticals has higher revenue and earnings than HUTCHMED. Dechra Pharmaceuticals is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dechra Pharmaceuticals£761.50M0.00-£27.90M-£0.25N/A
HUTCHMED£549.12M2.66-£52.98M£53.003.21

HUTCHMED has a net margin of 163.84% compared to Dechra Pharmaceuticals' net margin of -3.66%. HUTCHMED's return on equity of 36.88% beat Dechra Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Dechra Pharmaceuticals-3.66% -3.92% 0.75%
HUTCHMED 163.84%36.88%-5.90%

Dechra Pharmaceuticals has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.428, meaning that its share price is 57% less volatile than the broader market.

Summary

Dechra Pharmaceuticals beats HUTCHMED on 6 of the 10 factors compared between the two stocks.

How does HUTCHMED compare to Hikma Pharmaceuticals?

Hikma Pharmaceuticals (LON:HIK) and HUTCHMED (LON:HCM) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

63.6% of Hikma Pharmaceuticals shares are held by institutional investors. Comparatively, 20.4% of HUTCHMED shares are held by institutional investors. 21.9% of Hikma Pharmaceuticals shares are held by company insiders. Comparatively, 2.8% of HUTCHMED shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Hikma Pharmaceuticals currently has a consensus target price of GBX 1,687, indicating a potential upside of 6.44%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Hikma Pharmaceuticals is more favorable than HUTCHMED.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hikma Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
HUTCHMED
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. HUTCHMED is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hikma Pharmaceuticals£3.35B1.00£353.21M£181.008.76
HUTCHMED£549.12M2.66-£52.98M£53.003.21

HUTCHMED has a net margin of 163.84% compared to Hikma Pharmaceuticals' net margin of 12.00%. HUTCHMED's return on equity of 36.88% beat Hikma Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hikma Pharmaceuticals12.00% 15.83% 9.40%
HUTCHMED 163.84%36.88%-5.90%

Hikma Pharmaceuticals has a beta of 0.654, meaning that its share price is 35% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.428, meaning that its share price is 57% less volatile than the broader market.

In the previous week, Hikma Pharmaceuticals had 1 more articles in the media than HUTCHMED. MarketBeat recorded 1 mentions for Hikma Pharmaceuticals and 0 mentions for HUTCHMED. Hikma Pharmaceuticals' average media sentiment score of 0.00 equaled HUTCHMED'saverage media sentiment score.

Company Overall Sentiment
Hikma Pharmaceuticals Neutral
HUTCHMED Neutral

Summary

Hikma Pharmaceuticals beats HUTCHMED on 12 of the 15 factors compared between the two stocks.

How does HUTCHMED compare to Indivior?

HUTCHMED (LON:HCM) and Indivior (LON:INDV) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

In the previous week, Indivior had 1 more articles in the media than HUTCHMED. MarketBeat recorded 1 mentions for Indivior and 0 mentions for HUTCHMED. Indivior's average media sentiment score of 0.67 beat HUTCHMED's score of 0.00 indicating that Indivior is being referred to more favorably in the news media.

Company Overall Sentiment
HUTCHMED Neutral
Indivior Positive

Indivior has higher revenue and earnings than HUTCHMED. Indivior is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HUTCHMED£549.12M2.66-£52.98M£53.003.21
Indivior£1.40B1.38-£2.36M-£1.21N/A

HUTCHMED has a net margin of 163.84% compared to Indivior's net margin of 11.44%. HUTCHMED's return on equity of 36.88% beat Indivior's return on equity.

Company Net Margins Return on Equity Return on Assets
HUTCHMED163.84% 36.88% -5.90%
Indivior 11.44%-23.90%2.37%

HUTCHMED has a beta of 0.428, suggesting that its stock price is 57% less volatile than the broader market. Comparatively, Indivior has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market.

20.4% of HUTCHMED shares are owned by institutional investors. Comparatively, 86.0% of Indivior shares are owned by institutional investors. 2.8% of HUTCHMED shares are owned by company insiders. Comparatively, 3.4% of Indivior shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Indivior beats HUTCHMED on 7 of the 13 factors compared between the two stocks.

How does HUTCHMED compare to Vectura Group?

Vectura Group (LON:VEC) and HUTCHMED (LON:HCM) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

HUTCHMED has a net margin of 163.84% compared to Vectura Group's net margin of 0.00%. HUTCHMED's return on equity of 36.88% beat Vectura Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Vectura GroupN/A N/A N/A
HUTCHMED 163.84%36.88%-5.90%

In the previous week, Vectura Group's average media sentiment score of 0.00 equaled HUTCHMED'saverage media sentiment score.

Company Overall Sentiment
Vectura Group Neutral
HUTCHMED Neutral

20.4% of HUTCHMED shares are owned by institutional investors. 2.8% of HUTCHMED shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Vectura Group has higher earnings, but lower revenue than HUTCHMED. Vectura Group is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vectura Group£190.60M0.00N/A£20.10N/A
HUTCHMED£549.12M2.66-£52.98M£53.003.21

Summary

HUTCHMED beats Vectura Group on 6 of the 8 factors compared between the two stocks.

How does HUTCHMED compare to Ergomed?

Ergomed (LON:ERGO) and HUTCHMED (LON:HCM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

In the previous week, Ergomed's average media sentiment score of 0.00 equaled HUTCHMED'saverage media sentiment score.

Company Overall Sentiment
Ergomed Neutral
HUTCHMED Neutral

Ergomed has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.428, meaning that its stock price is 57% less volatile than the broader market.

Ergomed has higher earnings, but lower revenue than HUTCHMED. Ergomed is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ergomed£152.09M0.00£15M£0.29N/A
HUTCHMED£549.12M2.66-£52.98M£53.003.21

71.1% of Ergomed shares are owned by institutional investors. Comparatively, 20.4% of HUTCHMED shares are owned by institutional investors. 18.2% of Ergomed shares are owned by company insiders. Comparatively, 2.8% of HUTCHMED shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

HUTCHMED has a net margin of 163.84% compared to Ergomed's net margin of 9.87%. HUTCHMED's return on equity of 36.88% beat Ergomed's return on equity.

Company Net Margins Return on Equity Return on Assets
Ergomed9.87% 18.08% 10.16%
HUTCHMED 163.84%36.88%-5.90%

Summary

Ergomed beats HUTCHMED on 6 of the 10 factors compared between the two stocks.

Get HUTCHMED News Delivered to You Automatically

Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HCM vs. The Competition

Export
MetricHUTCHMEDPharmaceuticals IndustryHealthcare SectorLON Exchange
Market Cap£1.46B£11.74B£6.86B£2.82B
Dividend Yield4.63%2.73%2.59%6.15%
P/E Ratio3.21799.05282.27368.29
Price / Sales2.66749.34590.9183,501.30
Price / Cash2.4914.8228.6027.89
Price / Book1.9410.3910.937.04
Net Income-£52.98M£2.82B£3.49B£5.89B
7 Day Performance0.59%-0.18%-0.64%6.05%
1 Month Performance-4.49%-4.04%-3.78%-0.22%
1 Year Performance-35.61%156.15%61.99%63.72%

HUTCHMED Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HCM
HUTCHMED
N/AGBX 170
flat		N/A-35.6%£1.46B£549.12M3.211,760
DPH
Dechra Pharmaceuticals
N/AN/AN/AN/A£4.40B£761.50MN/A2,457
HIK
Hikma Pharmaceuticals
1.9174 of 5 stars		GBX 1,585
-0.6%		GBX 1,687
+6.4%		-18.0%£3.41B£3.35B8.769,100
INDV
Indivior
N/AGBX 1,238
+1.6%		N/A+0.0%£1.93B£1.40BN/A1,000
VEC
Vectura Group
N/AN/AN/AN/A£1.01B£190.60M8.209,200

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:HCM) was last updated on 8/3/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...
Brownstone Research | Sponsoredtc pixel
“The unseen winner of the AI race” is not SpaceX
Marc Chaikin - the analyst who called Nvidia before its historic run - says a tech firm labeled 'the unseen wi...
Chaikin Analytics | Sponsoredtc pixel